At Mundipharma Research, we develop therapies for patients around the world with rare or relapsed/refractory (difficult to treat) cancer, and investigate smart approaches to new cancer treatments, from concept through to clinical development and regulatory approval.

Mundipharma Research has a long heritage in oncology that has enabled us to bring together a team of passionate medical and operational oncology specialists, who work in partnership with a wide network of clinical experts and consultants.

Despite breakthroughs in treatment, there is still unmet patient need.

1 in 4 of all cancers are ‘rare’, with limited treatment options.1

Cancer can progress during therapy, becoming resistant to multiple treatments.2,3

Side effects may result in dose reduction or treatment discontinuation.4,5

Cancer relapses can occur if not all the cancer cells are killed, the effect of therapy lessens or the disease changes.6

Mundipharma Research is focussed on addressing these unmet needs with clinical trials ongoing in the following cancer types:

Blood cancers

Blood cancers affect the production and function of blood cells. They include cancers such as multiple myeloma, leukaemias and lymphomas.

  • Cutaneous T-cell lymphoma (CTCL)
  • Hodgkin lymphoma (HL)
  • Peripheral T-cell lymphoma (PTCL)
  • T-cell prolymphocytic leukaemia (T-PLL)
  • Multiple myeloma (MM)

Solid tumours

Solid tumours may be benign (non-cancerous) or malignant (cancerous). They are formed from a mass of tissue that does not include liquid and are named for the type of cells from which they originate. Solid tumours include sarcomas and carcinomas.

  • Biliary tract cancer
  • Ovarian cancer
  • Small cell lung cancer (SCLC)
  • Soft tissue sarcoma (STS)
  • Triple-negative breast cancer (TNBC)
  • Endometrial cancer

Oncology products being developed by Mundipharma Research and the Mundipharma network of independent associated companies:


Since 1st January 2020, the Mundipharma Early Development in Oncology development programme is run by Mundipharma Research.


  1. Rare Cancers Europe. https://www.rarecancerseurope.org/. Last accessed: December 2019
  2. American Cancer Society. https://www.cancer.org/treatment/survivorship-during-and-after-treatment/when-cancer-doesnt-go-away.html. Last accessed December 2019
  3. Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers 2014;6:1769–92
  4. Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol 9:245. doi: 10.3389/fphar.2018.00245
  5. ESMO. What are Immunotherapy Side Effects? https://www.esmo.org/content/download/124130/2352601/file/ESMO-Patient-Guide-on-Immunotherapy-Side-Effects.pdf. Last accessed December 2019
  6. Cancer Research UK. https://www.cancerresearchuk.org/about-cancer/what-is-cancer/why-some-cancers-come-back Last accessed December 2019

As of 1st January 2020, Mundipharma Early Development in Oncology is now part of Mundipharma R&D, with leadership and resources based at Mundipharma Research Limited. You have been re-directed to the Mundipharma Research website.

Please click to continue